Press release
Global Hepatocellular Carcinoma Drugs Market BY Focusing on Top Key companies Analysis- Amgen Inc., Celgen Corporation, Pfizer Inc., Teva Pharmaceutical Industries Ltd.,
Hepatocellular carcinoma (HCC) is a major type of primary liver cancer that originates from liver cells or hepatocytes. The disease occurs mainly in patients with hepatitis B, hepatitis C, cirrhosis, obesity and diabetes. The diagnosis of hepatocellular carcinoma is mainly performed by imaging tests such as ultrasound, magnetic resonance, computed tomography and liver biopsy. The treatment of hepatocellular carcinoma mainly includes radiotherapy, ablation therapy in addition to chemotherapy and targeted pharmacological therapy. The majority of HCC patients are diagnosed at the final stage of liver dysfunction. Due to the poor prognosis of the disease, the mortality rate is approximately the same as the incidence rate. Therefore, early detection of cancer is an important parameter to improve the survival of affected patients, which contributes to the growth of the global market for hepatocellular carcinoma drugs.
Browse report brief and TOC @ https://www.researchcosmos.com/reports/global-hepatocellular-carcinoma-drugs-market-outlook-2022-trends-and-developments/3380784
Global Hepatocellular Carcinoma Drugs Market Drivers and Restraints:
The increasing incidence of cases of global hepatocellular carcinoma is an important factor that increases market growth. According to research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common cancer in the world and the third most common cause of death in the world found in one-fifth of men and -eight of women. In addition, according to the University of Addis Ababa, 2017, hepatocellular carcinoma (HCC) accounts for 854,000 new cases of liver cancer and 810,000 deaths in 2015. In addition, the increase in the incidence and mortality of Hepatocellular carcinoma is attributed to the emergence of new risk factors such as viral hepatitis B and C, metabolic disorders such as diabetes and fatty liver disease and exposure to non-alcoholic toxins such as alcohol and aflatoxins. In addition, the clinical advances incorporated in regulatory approvals for new drugs to treat hepatocellular carcinoma increase the growth of the market. For example, in April 2017, the US Food and Drug Administration has extended the indications for regorafenib (Stivarga) manufactured by Bayer HealthCare Pharmaceuticals Inc., for the treatment of patients with hepatocellular carcinoma. The therapy showed a significant improvement in patient survival after failure of standard treatments. In addition, in 2017, the US FDA approved accelerated drug nivolumab (Opdivo) developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma.
However, side effects associated with medications such as anemia, constipation, low white blood cell count, pneumonia, etc. may limit the growth of the market.
Request free sample @ https://www.researchcosmos.com/request/global-hepatocellular-carcinoma-drugs-market-outlook-2022/3380784
Geographic Segmentation:
On the basis of geography, Global Hepatocellular Carcinoma Drugs Market is segmented into regions such as North America, Latin America, Europe, Middle East and Africa and Asia Pacific. North America is expected to maintain its dominant position in the global market for hepatocellular carcinoma due to the increasing prevalence of the disease and the increasing number of clinical trials conducted by manufacturers to meet medical needs. According to the University of California Los Angeles (UCLA) Department of Health Sciences survey in 2017, hepatocellular carcinoma (HCC) accounts for three-quarters of all liver cancers in the United States. With approximately 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths reported by the disease. In addition, in April 2018, Eli Lilly and Company completed the Phase 3 study of Cyramza (ramucirumab) as a unique agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer.
Asia-Pacific is expected to enter the global market for hepatocellular carcinoma medications due to the growing number of research and development activities by manufacturers in the region to develop effective therapies. For example, in February 2017, Daiichi Sankyo, a pharmaceutical company in Japan, completed the phase 3 study of tivantinib indicated for patients with hepatocellular carcinoma treated with other therapies.
Key Players in Global Hepatocellular Carcinoma Drugs Market:
Major players competing in Global Hepatocellular Carcinoma Drugs Market include Bayer AG, Novartis Pharmaceuticals, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, AbbVie Inc., Amgen Inc., Celgen Corporation, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. and others.
Inquire Before Buying @ https://www.researchcosmos.com/inquire/global-hepatocellular-carcinoma-drugs-market-outlook-2022/3380784
Scope of the report:
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.
About Us:
Research Cosmos is a provider of standard and customized market research, business intelligence and consulting services across more than 100 domains in different industries of the world. We host the trending market reports of the world’s top-notch publishing companies, offering services to a wide range of customers from students to fortune 500 companies and discloses the hidden opportunities in every leading industry of the world.
Contact:
Kevin Stewart
Global Sales Manager
Research Cosmos
www.researchcosmos.com
Blog: https://acutemarketinsights.com
Blog: https://marketreportsweb.com/
kevin@researchcosmos.com
+1 888 709 8757
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Hepatocellular Carcinoma Drugs Market BY Focusing on Top Key companies Analysis- Amgen Inc., Celgen Corporation, Pfizer Inc., Teva Pharmaceutical Industries Ltd., here
News-ID: 1257068 • Views: …
More Releases from Research Cosmos
Mobile Phone Insurance Market Size to Reach USD 32.24 Bn By 2025
The size of the Global mobile phone insurance market is estimated to reach USD 32.24 billion by 2025, growing at a CAGR of 12.5%, as per the recently published report by Research Cosmos. It is worth to claim insurance for mobile phones as we are spending a lot of money on purchasing. The policies include accidental damage, water damage, and screen cracking.
Browse details of the report @ https://www.researchcosmos.com/reports/mobile-phone-insurance-market/199557834
Growing utilization…
Social Employee Recognition Systems Market Predicted to grow at a CAGR of xx By …
Social Employee Recognition Systems Market Analysis Size, Growth rate and Overview:
Social Employee Recognition Systems Market was valued at USD xx million in 2018 and is expected to reach almost USD xx million by the end of 2025, growing at a CAGR of around xx% over the predicted period.
Throughout the world, social employee recognition systems have expanded dramatically to address the need to move away from traditional methods and programs of…
More Releases for Hepatocellular
Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in…
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatocellular…
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027
This latest report researches the industry structure, sales, revenue,…
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
